Cargando…
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median age at diagnosis of 70 years old. A mainstay of multiple myeloma treatment is lenalidomide, which is an immunomodulatory drug (IMiD) that changed the treatment paradigm for multiple myeloma. This is p...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210019/ https://www.ncbi.nlm.nih.gov/pubmed/32440105 http://dx.doi.org/10.2147/CIA.S196087 |